Tralokinumab for Eczema: What ECZTRA 1 and 2 Tell Us About Response
DOCTOR’S NOTES · ECZEMA RESEARCH
When topical prescriptions do not adequately control moderate-to-severe atopic dermatitis, a dermatologist may discuss tralokinumab, an injected medicine targeting interleukin-13. Its evidence is specific to a treatment, population and follow-up period. A headline saying that responders stayed well for a year does not mean that everyone who started treatment reached the same result.
Who participated in the original trials?
The ECZTRA 1 and ECZTRA 2 publication, appearing in the British Journal of Dermatology in 2021, reported two randomized, double-blind, placebo-controlled trials in adults with moderate-to-severe eczema. They enrolled 802 and 794 participants, respectively. The initial comparison assessed tralokinumab monotherapy against placebo over 16 weeks. Rescue treatment and the rules for counting responses are important parts of the design.
| Week-16 outcome | ECZTRA 1: tralokinumab / placebo | ECZTRA 2: tralokinumab / placebo |
|---|---|---|
| Clear or almost clear: IGA 0 or 1 | 15.8% / 7.1% | 22.2% / 10.9% |
| At least 75% EASI improvement | 25.0% / 12.7% | 33.2% / 11.4% |
The study also followed eligible responders through a maintenance period. Those findings concern people who first met response criteria, not every participant at enrollment. The full trial report describes the treatment pathways and analysis populations.
Why two response measures can give different percentages
A large reduction from baseline and being clear or almost clear are different achievements. Someone starting with extensive disease can improve substantially while still having visible eczema. Neither outcome alone captures all the effects on sleep, hand use or daily comfort. Keep the measure, comparison group and time point attached to a result when discussing it.
It is also unhelpful to rank this medicine against another biologic using isolated percentages from separate trials. The populations, rescue rules and accompanying treatments may differ. A prescriber can explain which evidence is relevant to the person's actual situation and which comparisons remain uncertain.
How does the current label relate to these adult studies?
The U.S. ADBRY prescribing information, revised December 2025, includes eligible adults and patients age 12 and older whose moderate-to-severe disease is inadequately controlled by topical prescriptions or when those treatments are inadvisable. It permits use with or without topical corticosteroids. The original adult trials should not be presented as infant evidence.
The label discusses hypersensitivity, conjunctivitis and keratitis, helminth infections and live-vaccine precautions. Report new or worsening eye symptoms to the care team. Severe allergic symptoms require immediate medical help. Ask the prescriber how vaccine planning and other medicines affect the individual plan rather than independently changing treatment.
Prepare a practical review plan
Before starting, ask which outcomes will be checked and when. Bring an accurate list of previous treatments, including whether each was ineffective, uncomfortable, difficult to obtain or hard to use consistently. These are different barriers and can lead to different solutions. Discuss injection training, storage instructions, follow-up access and costs before those details become obstacles.
Use dated observations to describe what remains difficult even if the skin looks improved. Ask whether the accompanying topical routine should continue and whom to contact between appointments. The goal is an understandable care plan, not achieving a number from a study table.
Our lebrikizumab ADvocate guide discusses another IL-13-targeted medicine and its own evidence. The EASI-75 explanation helps interpret improvement thresholds without treating them as cure rates.
Read the related evidence
For another systemic comparison, read the JADE COMPARE early-itch evidence. The ADAPT pediatric study illustrates why a trial finding does not itself create a labeled eczema indication.
Dr. Arsy Moisturizer #003, 4 oz is a cosmetic moisturizer for hydration and moisture-barrier support. The prescription studies discussed here did not test #003 and do not establish that it treats, cures or prevents eczema. Follow the current product directions and your prescriber’s instructions for order and timing with topical medicines. For a child, ask the pediatrician which skin-care products are suitable.
Prepared by the Dr. Arsy editorial team. Sources checked November 8, 2026. Educational information supports a conversation with a qualified clinician and does not prescribe for an individual. No independent clinician review is claimed. The AI-created sports image is an editorial product illustration, not a clinical outcome or a photograph of a patient. Cited researchers and organizations do not endorse Dr. Arsy.